L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 133.18 billion. The enterprise value is 130.24 billion.

Market Cap	133.18B
Enterprise Value	130.24B

Important Dates

The next estimated earnings date is Monday, March 17, 2025.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 19.94 million shares outstanding. The number of shares has increased by 37.35% in one year.

Current Share Class	n/a
Shares Outstanding	19.94M
Shares Change (YoY)	+37.35%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	13.38%
Owned by Institutions (%)	0.54%
Float	17.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.02
PB Ratio	3.51
P/TBV Ratio	3.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.96, with an EV/FCF ratio of -10.88.

EV / Earnings	-86.82
EV / Sales	3.92
EV / EBITDA	26.96
EV / EBIT	63.61
EV / FCF	-10.88

Financial Position

The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.68.

Current Ratio	1.53
Quick Ratio	0.85
Debt / Equity	0.68
Debt / EBITDA	4.34
Debt / FCF	-1.86
Interest Coverage	1.03

Financial Efficiency

Return on equity (ROE) is -14.74% and return on invested capital (ROIC) is 2.70%.

Return on Equity (ROE)	-14.74%
Return on Assets (ROA)	2.07%
Return on Capital (ROIC)	2.70%
Revenue Per Employee	553.07M
Profits Per Employee	-25.00M
Employee Count	60
Asset Turnover	0.47
Inventory Turnover	0.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.18% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-32.18%
50-Day Moving Average	6,898.80
200-Day Moving Average	8,030.65
Relative Strength Index (RSI)	47.47
Average Volume (20 Days)	35,022

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 33.18 billion and -1.50 billion in losses. Loss per share was -75.11.

Revenue	33.18B
Gross Profit	28.66B
Operating Income	2.35B
Pretax Income	-6.97B
Net Income	-1.50B
EBITDA	5.13B
EBIT	2.35B
Loss Per Share	-75.11

Full Income Statement

Balance Sheet

The company has 20.16 billion in cash and 22.27 billion in debt, giving a net cash position of -2.11 billion or -105.98 per share.

Cash & Cash Equivalents	20.16B
Total Debt	22.27B
Net Cash	-2.11B
Net Cash Per Share	-105.98
Equity (Book Value)	32.93B
Book Value Per Share	1,904.93
Working Capital	19.66B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.47 billion and capital expenditures -1.49 billion, giving a free cash flow of -11.97 billion.

Operating Cash Flow	-10.47B
Capital Expenditures	-1.49B
Free Cash Flow	-11.97B
FCF Per Share	-600.16

Full Cash Flow Statement

Margins

Gross margin is 86.36%, with operating and profit margins of 7.07% and -4.52%.

Gross Margin	86.36%
Operating Margin	7.07%
Pretax Margin	-21.01%
Profit Margin	-4.52%
EBITDA Margin	15.46%
EBIT Margin	7.07%
FCF Margin	n/a

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-37.35%
Shareholder Yield	-37.35%
Earnings Yield	-1.12%
FCF Yield	-8.98%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 1.91. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.91
Piotroski F-Score	n/a